

Figure 1




Figure 2

YRPRPRRY ●
 TYRPRPRRY *
 YRPRPRRYV ◇
 TYRPRPRRYV ○
 RPRPRRYVE ▽
 MSWRGRSTYRPRPRR ◆




Figure 3

VDE 44

VDE 43

VDE 24

←

GAGE-1 GTTGCCACAGACTGGGATTCTCTGGCTTTA ATGAACATTCCTCTTAAATCTTCCCA CCGAACCTGAGTGACTGAAATATCAAA
 GAGE-2
 GAGE-3
 GAGE-4
 GAGE-5
 GAGE-6

GAGE-1	GGGGAGAGACCGTTTAGTTCCTATCATCTG	TGGCAATGTGAAGGSCAATCCAGGTGTAA	AGAAAGCACTGTGAATGTGCAGGCTGCT
GAGE-2
GAGE-3
GAGE-4
GAGE-5
GAGE-6

GAGE-1	CCATATGTTGGAAA	TTTGTCAATTA	AAATTC	TCCCAATTAAGGCTTTACAGCCGTTCTGCAAA	GTAAAAA
GAGE-2	CCATATGTTGGAAA	TTTGTCAATTA	AAATTC	TCCCAATTAAGGCTTTACAGCCGTTCTGCAAA	GTAAAAA
GAGE-3	CCATATGTTGGAAA	TTTGTCAATTA	AAATTC	TCCCAATTAAGGCTTTACAGCCGTTCTGCAAA	GTAAAAA
GAGE-4	CCATATGTTGGAAA	TTTGTCAATTA	AAATTC	TCCCAATTAAGGCTTTACAGCCGTTCTGCAAA	GTAAAAA
GAGE-5	CCATATGTTGGAAA	TTTGTCAATTA	AAATTC	TCCCAATTAAGGCTTTACAGCCGTTCTGCAAA	GTAAAAA
GAGE-6	CCATATGTTGGAAA	TTTGTCAATTA	AAATTC	TCCCAATTAAGGCTTTACAGCCGTTCTGCAAA	GTAAAAA

Figure 4

antigenic
peptide

GAGE-1	MS-WRGST- <u>LP</u> PRRYV- <u>PE</u> MI	GFMRFEQFSDEVLPATPEEGEPATQ	RQDPAAAQEGEGEGASAGQGPKPEA	7
GAGE-2	MS-WRGST- <u>LP</u> PRRYV- <u>PE</u> MI	GFMRFEQFSDEVLPATPEEGEPATQ	RQDPAAAQEGEGEGASAGQGPKPEA	7
GAGE-3	MS-WRGST- <u>LP</u> PRRYV- <u>PE</u> MI	GFMRFEQFSDEVLPATPEEGEPATQ	RQDPAAAQEGEGEGASAGQGPKPEA	7
GAGE-4	MS-WRGST- <u>LP</u> PRRYV- <u>PE</u> MI	GFMRFEQFSDEVLPATPEEGEPATQ	RQDPAAAQEGEGEGASAGQGPKPEA	7
GAGE-5	MS-WRGST- <u>LP</u> PRRYV- <u>PE</u> MI	GFMRFEQFSDEVLPATPEEGEPATQ	RQDPAAAQEGEGEGASAGQGPKPEA	7
GAGE-6	MS-WRGST- <u>LP</u> PRRYV- <u>PE</u> MI	GFMRFEQFSDEVLPATPEEGEPATQ	RQDPAAAQEGEGEGASAGQGPKPEA	7
GAGE-1	DSQEQGHPTGCECEDGPDGQEL- <u>OP</u>	PNPEEVKTPEEGEKQSQSQC	13
GAGE-2	ESQEQGHPTGCECEDGPDGQEL- <u>OP</u>	PNPEEVKTPEEGEKQSQSQC	11
GAGE-3	DSQEQGHPTGCECEDGPDGQEL- <u>OP</u>	PNPEEVKTPEEGEKQSQSQC	11
GAGE-4	DSQEQGHPTGCECEDGPDGQEL- <u>OP</u>	PNPEEVKTPEEGEKQSQSQC	11
GAGE-5	DSQEQGHPTGCECEDGPDGQEL- <u>OP</u>	PNPEEVKTPEEGEKQSQSQC	11
GAGE-6	DSQEQGHPTGCECEDGPDGQEL- <u>OP</u>	PNPEEVKTPEEGEKQSQSQC	11

Figure 5




Figure 6




Figure 7. Stimulation of MZ2-CTL 22/23 by COS-7 cells transiently transfected with an HLA-A29 cDNA and MAGE, BAGE or GAGE cDNA. The CTL was added after 24 hours and the production of TNF was estimated 24 hours later. MZ2-MEL.43 was used as a positive control stimulator cell.




Figure 6 Lysis by MZ2-CTL 22/23 of lymphoblastoid cell line LB17-EBV incubated with GAGE-encoded peptide YYWRPRRY. Thousand ^{51}Cr -labelled LB17-EBV target cells were incubated in 96 well microplates in the presence of various concentrations of peptide for 15 minutes at 37°C . An equal volume containing 6000 CTL was then added. Chromium release was measured after 4 hours at 37°C . We have indicated the final concentration of peptides during the incubation of the target cells with the CTL. The arrow indicates the percentage of lysis of MZ2-MEL.43 cells.